GUTS Stock Overview
A metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Fractyl Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.02 |
| 52 Week High | US$14.50 |
| 52 Week Low | US$1.74 |
| Beta | 0 |
| 1 Month Change | -12.55% |
| 3 Month Change | -12.55% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.28% |
Recent News & Updates
Shareholder Returns
| GUTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.9% | 1.6% | 1.3% |
| 1Y | n/a | 9.5% | 24.4% |
Return vs Industry: Insufficient data to determine how GUTS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how GUTS performed against the US Market.
Price Volatility
| GUTS volatility | |
|---|---|
| GUTS Average Weekly Movement | 14.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GUTS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GUTS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 122 | Harith Rajagopalan | fractyl.com |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. Fundamentals Summary
| GUTS fundamental statistics | |
|---|---|
| Market cap | US$99.08m |
| Earnings (TTM) | -US$68.97m |
| Revenue (TTM) | US$97.00k |
1,002x
P/S Ratio-1.4x
P/E RatioIs GUTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUTS income statement (TTM) | |
|---|---|
| Revenue | US$97.00k |
| Cost of Revenue | US$52.00k |
| Gross Profit | US$45.00k |
| Other Expenses | US$69.02m |
| Earnings | -US$68.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 46.39% |
| Net Profit Margin | -71,104.12% |
| Debt/Equity Ratio | 60.2% |
How did GUTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 23:50 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fractyl Health, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Umer Raffat | Evercore ISI |
| Michael Ulz | Morgan Stanley |